Aurinia Pharmaceuticals Inc (AUPH) Rating Reiterated by Seaport Global Securities

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP)‘s stock had its “buy” rating restated by stock analysts at Seaport Global Securities in a note issued to investors on Friday, Marketbeat.com reports. They currently have a $10.00 price target on the biotechnology company’s stock. Seaport Global Securities’ price target points to a potential upside of 55.76% from the company’s current price.

AUPH has been the topic of a number of other research reports. Vetr downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.74 price target on the stock. in a report on Monday, July 31st. Zacks Investment Research raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a report on Tuesday, August 15th. Cantor Fitzgerald set a $14.00 price target on shares of Aurinia Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 11th. Finally, BidaskClub downgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 28th. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Aurinia Pharmaceuticals has a consensus rating of “Buy” and an average target price of $9.82.

Shares of Aurinia Pharmaceuticals (NASDAQ AUPH) opened at 6.42 on Friday. The stock’s market capitalization is $535.97 million. Aurinia Pharmaceuticals has a 52 week low of $2.02 and a 52 week high of $10.54. The company’s 50 day moving average is $6.32 and its 200-day moving average is $6.56.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.10. The company had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.06 million. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%. On average, equities analysts predict that Aurinia Pharmaceuticals will post ($1.01) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Aurinia Pharmaceuticals Inc (AUPH) Rating Reiterated by Seaport Global Securities” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://ledgergazette.com/2017/10/07/aurinia-pharmaceuticals-inc-auph-coverage-initiated-by-analysts-at-seaport-global-securities.html.

A number of large investors have recently modified their holdings of the business. AWM Investment Company Inc. lifted its holdings in Aurinia Pharmaceuticals by 17.5% during the second quarter. AWM Investment Company Inc. now owns 352,500 shares of the biotechnology company’s stock valued at $2,161,000 after purchasing an additional 52,500 shares in the last quarter. Redmile Group LLC lifted its holdings in Aurinia Pharmaceuticals by 137.0% during the second quarter. Redmile Group LLC now owns 332,310 shares of the biotechnology company’s stock valued at $2,037,000 after purchasing an additional 192,067 shares in the last quarter. Kazazian Asset Management LLC lifted its holdings in Aurinia Pharmaceuticals by 47.3% during the second quarter. Kazazian Asset Management LLC now owns 66,304 shares of the biotechnology company’s stock valued at $406,000 after purchasing an additional 21,304 shares in the last quarter. Royal Bank of Canada lifted its holdings in Aurinia Pharmaceuticals by 8.6% during the second quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 1,341 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in Aurinia Pharmaceuticals by 357.3% during the second quarter. Goldman Sachs Group Inc. now owns 876,461 shares of the biotec

AUPH has been the topic of a number of other research reports. Vetr downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.74 price target on the stock. in a report on Monday, July 31st. Zacks Investment Research raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a report on Tuesday, August 15th. Cantor Fitzgerald set a $14.00 price target on shares of Aurinia Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 11th. Finally, BidaskClub downgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 28th. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Aurinia Pharmaceuticals has a consensus rating of “Buy” and an average target price of $9.82.

Shares of Aurinia Pharmaceuticals (NASDAQ AUPH) opened at 6.42 on Friday. The stock’s market capitalization is $535.97 million. Aurinia Pharmaceuticals has a 52 week low of $2.02 and a 52 week high of $10.54. The company’s 50 day moving average is $6.32 and its 200-day moving average is $6.56.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.10. The company had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.06 million. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%. On average, equities analysts predict that Aurinia Pharmaceuticals will post ($1.01) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Aurinia Pharmaceuticals Inc (AUPH) Rating Reiterated by Seaport Global Securities” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://ledgergazette.com/2017/10/07/aurinia-pharmaceuticals-inc-auph-coverage-initiated-by-analysts-at-seaport-global-securities.html.

A number of large investors have recently modified their holdings of the business. AWM Investment Company Inc. lifted its holdings in Aurinia Pharmaceuticals by 17.5% during the second quarter. AWM Investment Company Inc. now owns 352,500 shares of the biotechnology company’s stock valued at $2,161,000 after purchasing an additional 52,500 shares in the last quarter. Redmile Group LLC lifted its holdings in Aurinia Pharmaceuticals by 137.0% during the second quarter. Redmile Group LLC now owns 332,310 shares of the biotechnology company’s stock valued at $2,037,000 after purchasing an additional 192,067 shares in the last quarter. Kazazian Asset Management LLC lifted its holdings in Aurinia Pharmaceuticals by 47.3% during the second quarter. Kazazian Asset Management LLC now owns 66,304 shares of the biotechnology company’s stock valued at $406,000 after purchasing an additional 21,304 shares in the last quarter. Royal Bank of Canada lifted its holdings in Aurinia Pharmaceuticals by 8.6% during the second quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 1,341 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in Aurinia Pharmaceuticals by 357.3% during the second quarter. Goldman Sachs Group Inc. now owns 876,461 shares of the biotechnology company’s stock valued at $5,373,000 after purchasing an additional 684,816 shares in the last quarter. 27.76% of the stock is currently owned by institutional investors and hedge funds.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply